Study of Pembrolizumab (MK-3475) for High Risk Oral Intra-Epithelial Neoplasias

Conditions:   Oral Pre-malignant Lesion(s);   Intra-epithelial Neoplasias;   History of Invasive Oral Cancer
Intervention:   Drug: Pembrolizumab
Sponsors:   M.D. Anderson Cancer Center;   Merck Sharp & Dohme Corp.
Not yet recruiting - verified August 2016

from #ENT via xlomafota13 on Inoreader http://ift.tt/2bXk6cl
via IFTTT